Systemic investigational therapies as adjuvants to surgery in patients with operable lung cancer

Jr Bunn P.A., Karen Kelly

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Early resection of lung cancers confined to the chest remains the best means of curing patients. Nonetheless, cure rates for resected patients are less than 50% overall, primarily due to the presence of occult distant metastases at the time of resection that subsequently manifest as relapse at distant sites. In approximately 20% of patients, local failure occurs within the chest. Chest radiotherapy reduces and nearly eliminates local failure, but does not improve survival or cure rates. Effective systemic chemotherapy is the cornerstone to improving survival and cure rates for early stage lung cancer. Recent studies showed that the preoperative use of cisplatin-based chemotherapy improved survival and 3-year disease-free survival in stage IIIA non-small cell lung cancer. New drugs such as paclitaxel and gemcitabine appear to improve survival in stages IIIB and IV non-small cell lung cancer. These agents will be tested in the surgical setting in the near future.

Original languageEnglish (US)
JournalSeminars in Oncology
Volume24
Issue number3 SUPPL. 8
StatePublished - 1997
Externally publishedYes

Fingerprint

Investigational Therapies
Lung Neoplasms
Thorax
gemcitabine
Non-Small Cell Lung Carcinoma
Survival
Drug Therapy
Paclitaxel
Cisplatin
Disease-Free Survival
Radiotherapy
Survival Rate
Neoplasm Metastasis
Recurrence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology

Cite this

Systemic investigational therapies as adjuvants to surgery in patients with operable lung cancer. / Bunn P.A., Jr; Kelly, Karen.

In: Seminars in Oncology, Vol. 24, No. 3 SUPPL. 8, 1997.

Research output: Contribution to journalArticle

@article{88e6947b8d8c4cfc940b12ec53803bb8,
title = "Systemic investigational therapies as adjuvants to surgery in patients with operable lung cancer",
abstract = "Early resection of lung cancers confined to the chest remains the best means of curing patients. Nonetheless, cure rates for resected patients are less than 50{\%} overall, primarily due to the presence of occult distant metastases at the time of resection that subsequently manifest as relapse at distant sites. In approximately 20{\%} of patients, local failure occurs within the chest. Chest radiotherapy reduces and nearly eliminates local failure, but does not improve survival or cure rates. Effective systemic chemotherapy is the cornerstone to improving survival and cure rates for early stage lung cancer. Recent studies showed that the preoperative use of cisplatin-based chemotherapy improved survival and 3-year disease-free survival in stage IIIA non-small cell lung cancer. New drugs such as paclitaxel and gemcitabine appear to improve survival in stages IIIB and IV non-small cell lung cancer. These agents will be tested in the surgical setting in the near future.",
author = "{Bunn P.A.}, Jr and Karen Kelly",
year = "1997",
language = "English (US)",
volume = "24",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "3 SUPPL. 8",

}

TY - JOUR

T1 - Systemic investigational therapies as adjuvants to surgery in patients with operable lung cancer

AU - Bunn P.A., Jr

AU - Kelly, Karen

PY - 1997

Y1 - 1997

N2 - Early resection of lung cancers confined to the chest remains the best means of curing patients. Nonetheless, cure rates for resected patients are less than 50% overall, primarily due to the presence of occult distant metastases at the time of resection that subsequently manifest as relapse at distant sites. In approximately 20% of patients, local failure occurs within the chest. Chest radiotherapy reduces and nearly eliminates local failure, but does not improve survival or cure rates. Effective systemic chemotherapy is the cornerstone to improving survival and cure rates for early stage lung cancer. Recent studies showed that the preoperative use of cisplatin-based chemotherapy improved survival and 3-year disease-free survival in stage IIIA non-small cell lung cancer. New drugs such as paclitaxel and gemcitabine appear to improve survival in stages IIIB and IV non-small cell lung cancer. These agents will be tested in the surgical setting in the near future.

AB - Early resection of lung cancers confined to the chest remains the best means of curing patients. Nonetheless, cure rates for resected patients are less than 50% overall, primarily due to the presence of occult distant metastases at the time of resection that subsequently manifest as relapse at distant sites. In approximately 20% of patients, local failure occurs within the chest. Chest radiotherapy reduces and nearly eliminates local failure, but does not improve survival or cure rates. Effective systemic chemotherapy is the cornerstone to improving survival and cure rates for early stage lung cancer. Recent studies showed that the preoperative use of cisplatin-based chemotherapy improved survival and 3-year disease-free survival in stage IIIA non-small cell lung cancer. New drugs such as paclitaxel and gemcitabine appear to improve survival in stages IIIB and IV non-small cell lung cancer. These agents will be tested in the surgical setting in the near future.

UR - http://www.scopus.com/inward/record.url?scp=0030979894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030979894&partnerID=8YFLogxK

M3 - Article

VL - 24

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 3 SUPPL. 8

ER -